Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion | Zendy

Ingrid U. Scott | Zendy; Paul VanVeldhuisen | Zendy; Michael S. Ip | Zendy; Barbara A. Blodi | Zendy; Neal L. Oden | Zendy; Carl C. Awh | Zendy; Derek Kunimoto | Zendy; Dennis M. Marcus | Zendy; John J. Wroblewski | Zendy; Jacqueline S. King | Zendy

Open Access

Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion

Author(s) -

Ingrid U. Scott,

Paul VanVeldhuisen,

Michael S. Ip,

Barbara A. Blodi,

Neal L. Oden,

Carl C. Awh,

Derek Kunimoto,

Dennis M. Marcus,

John J. Wroblewski,

Jacqueline S. King

Publication year - 2017

Publication title -

jama

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.688

H-Index - 680

eISSN - 1538-3598

pISSN - 0098-7484

DOI - 10.1001/jama.2017.4568

Subject(s) - aflibercept , medicine , central retinal vein occlusion , visual acuity , bevacizumab , macular edema , randomized controlled trial , randomization , ophthalmology , branch retinal vein occlusion , confidence interval , retinal vein , surgery , chemotherapy

Studies have established the efficacy and safety of aflibercept for the treatment of macular edema due to central retinal vein occlusion. Bevacizumab is used off-label to treat this condition despite the absence of supporting data.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research